Ensysce Biosciences Inc (ENSC) Stock Price, Quote & News

Company Profile

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 263 4196

Website: www.ensysce.com

Address:

7946 Ivanhoe Avenue, Suite 201, La Jolla, United States

BridgeLoanB Dec. 25 at 7:32 AM

$ENSC Forward momentum is increasingly dictated by operational clarity, while valuation increasingly tracks execution consistency. Proof points carry more weight than guidance alone.

0 · Reply

EnsysceBiosciences Dec. 24 at 8:04 PM

$ENSC Our recently announced pivotal milestone is highly encouraging, as the first patient has been enrolled in the PF614 Phase 3 program: - Multicenter, randomized, double-blind, placebo controlled trial for moderate to severe post-abdominoplasty pain - Enrollment commenced at leading clinical sites under expert principal investigators - Marks a key step toward redefining post-surgical opioid therapy with next-generation PF614, designed to provide reliable pain relief with unique safety profile These developments highlight Ensysce’s commitment to advancing safer, more effective pain management for millions of patients. #Ensysce #PF614 #Phase3 #ClinicalData #PainManagement #OpioidSafety #BiotechStocks #Investing #Healthcare

0 · Reply

ttesty Dec. 24 at 12:15 PM

$ENSC will be non-compliant on NASDAQ in 2-3 months. Predict $0.85 in next 2.5 months.

0 · Reply

ttesty Dec. 24 at 4:11 AM

Pfizer could scoop up $ENSC for $0.50/share before they get de-listed.

1 · Reply

Ensysce_Responder Dec. 24 at 1:55 AM

$ENSC Ensysce is actively advancing its programs: • Phase 3 trial started for PF614, a next-gen opioid designed to reduce abuse and overdose risk. • Overdose-protection MPAR program Supported by $15 Million 3-year NIDA grant. . • Recent financing secured: $4M raised, with up to $16M in future tranches. The company is executing our clinical strategy as planned.

1 · Reply

EnsysceBiosciences Dec. 24 at 1:48 AM

$ENSC PF614’s design is a potential game-changer in post-surgical pain management, combining strong efficacy with enhanced safety features. #Ensysce #PF614 #OpioidSafety #PainManagement #BiotechNews #NextGenTherapy

0 · Reply

FullPorrtDipz Dec. 23 at 7:35 PM

If you like getting in them before the massive moves.. Drop @MomentumZeus a FOLLOW below. He's been calling some insane runners lately.. 🚀 Accumualte mode on $ENSC $VISL $FEMY $OCEA

0 · Reply

ttesty Dec. 23 at 2:39 PM

$ENSC almost $1.. Keep shorting!

0 · Reply

ttesty Dec. 23 at 12:24 PM

$ENSC let's see some news so I can stop shorting :) Prolly 1 year or so until some preliminary phase 3 results and more dilution.

3 · Reply

ttesty Dec. 22 at 2:44 PM

$ENSC shorting these shares is an investment!

0 · Reply

Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)

Dec 9, 2025, 8:00 AM EST - 15 days ago

Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid

Dec 2, 2025, 8:00 AM EST - 22 days ago

Ensysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology

Nov 20, 2025, 8:00 AM EST - 4 weeks ago

Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach

Nov 17, 2025, 8:05 AM EST - 5 weeks ago

Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs

Nov 14, 2025, 4:15 PM EST - 5 weeks ago

Ensysce Biosciences Reports Third Quarter 2025 Financial Results

Oct 10, 2025, 8:00 AM EDT - 2 months ago

Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025

Sep 4, 2025, 8:00 AM EDT - 3 months ago

Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium

Aug 19, 2025, 8:00 AM EDT - 4 months ago

Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025

Aug 13, 2025, 4:15 PM EDT - 4 months ago

Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates

Jul 31, 2025, 8:00 AM EDT - 5 months ago

Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback

Jul 16, 2025, 8:00 AM EDT - 5 months ago

Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse

Jun 24, 2025, 8:00 AM EDT - 6 months ago

Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2

Jun 11, 2025, 8:00 AM EDT - 7 months ago

Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025

Jun 4, 2025, 8:00 AM EDT - 7 months ago

Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection

May 13, 2025, 4:15 PM EDT - 8 months ago

Ensysce Biosciences Reports First Quarter 2025 Financial Results

May 12, 2025, 8:00 AM EDT - 8 months ago

Ensysce Biosciences Bolsters Management Team with Regulatory Expert

Apr 24, 2025, 4:15 PM EDT - 8 months ago

Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

Apr 23, 2025, 5:11 PM EDT - 8 months ago

Ensysce Biosciences Stock Doubles In One Trading Session - Here's Why

Apr 23, 2025, 4:41 PM EDT - 8 months ago

Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds

Apr 23, 2025, 8:00 AM EDT - 8 months ago

Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder

Apr 15, 2025, 8:00 AM EDT - 9 months ago

Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study

Mar 31, 2025, 8:00 AM EDT - 9 months ago

Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Mar 18, 2025, 8:00 AM EDT - 10 months ago

Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain

Mar 10, 2025, 4:15 PM EDT - 10 months ago

Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 5, 2025, 8:00 AM EST - 10 months ago

Ensysce Biosciences to Participate in the 37th Annual ROTH Conference

Mar 3, 2025, 9:43 AM EST - 10 months ago

Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids

Feb 5, 2025, 8:00 AM EST - 11 months ago

Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment

Jan 22, 2025, 8:00 AM EST - 1 year ago

Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR

Jan 8, 2025, 8:00 AM EST - 1 year ago

Ensysce Biosciences Issues Annual Shareholder Letter

Dec 23, 2024, 8:00 AM EST - 1 year ago

Ensysce Biosciences Regains Full Compliance with Nasdaq

Dec 10, 2024, 8:00 AM EST - 1 year ago

Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product

Dec 4, 2024, 8:00 AM EST - 1 year ago

Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR

Dec 3, 2024, 4:15 PM EST - 1 year ago

Ensysce Biosciences Announces 1-for-15 Reverse Stock Split

Nov 26, 2024, 8:00 AM EST - 1 year ago

Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial

Nov 12, 2024, 4:15 PM EST - 1 year ago

Ensysce Biosciences Reports Third Quarter 2024 Financial Results

Nov 7, 2024, 8:00 AM EST - 1 year ago

Ensysce Biosciences Receives Positive Nasdaq Listing Determination

Oct 8, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Announces Leadership Team's Participation in the Annual Pain Therapeutics Summit

Oct 2, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries

Sep 27, 2024, 4:30 PM EDT - 1 year ago

Ensysce Biosciences Receives Notice from Nasdaq

Sep 24, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Presenting at Upcoming Meetings

Sep 19, 2024, 7:00 AM EDT - 1 year ago

Ensysce Biosciences Submits Phase 3 Protocol to the FDA

Sep 13, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024

Aug 29, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences, Inc. Announces $5 Million Concurrent Registered Direct Offering and Exercise of Warrants

Aug 27, 2024, 2:30 PM EDT - 1 year ago

Ensysce Biosciences Announces IRB Approval for Key MPAR Study

Aug 27, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Receives $14 Million NIH Grant for Clinical Development of Novel Opioid with Overdose Protection

Aug 14, 2024, 4:15 PM EDT - 1 year ago

Ensysce Biosciences Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 8:25 AM EDT - 1 year ago

Ensysce Biosciences Provides Key Themes Following IASP 2024 Symposium

Jul 23, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Provides Mid-Year 2024 Update

Jul 9, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Hosts IASP 2024 Symposium and Presents Clinical Dataset

BridgeLoanB Dec. 25 at 7:32 AM

$ENSC Forward momentum is increasingly dictated by operational clarity, while valuation increasingly tracks execution consistency. Proof points carry more weight than guidance alone.

0 · Reply

EnsysceBiosciences Dec. 24 at 8:04 PM

0 · Reply

ttesty Dec. 24 at 12:15 PM

$ENSC will be non-compliant on NASDAQ in 2-3 months. Predict $0.85 in next 2.5 months.

0 · Reply

ttesty Dec. 24 at 4:11 AM

Pfizer could scoop up $ENSC for $0.50/share before they get de-listed.

1 · Reply

Ensysce_Responder Dec. 24 at 1:55 AM

1 · Reply

EnsysceBiosciences Dec. 24 at 1:48 AM

0 · Reply

FullPorrtDipz Dec. 23 at 7:35 PM

If you like getting in them before the massive moves.. Drop @MomentumZeus a FOLLOW below. He's been calling some insane runners lately.. 🚀 Accumualte mode on $ENSC $VISL $FEMY $OCEA

0 · Reply

ttesty Dec. 23 at 2:39 PM

$ENSC almost $1.. Keep shorting!

0 · Reply

ttesty Dec. 23 at 12:24 PM

$ENSC let's see some news so I can stop shorting :) Prolly 1 year or so until some preliminary phase 3 results and more dilution.

3 · Reply

ttesty Dec. 22 at 2:44 PM

$ENSC shorting these shares is an investment!

0 · Reply

garrulous Dec. 22 at 2:23 PM

$ENSC holding or buying these shares is a donation not an investment.

0 · Reply

EnsysceBiosciences Dec. 21 at 2:37 PM

$ENSC The newly allowed MPAR® patent is not only relevant for our opioid candidates, it also covers broader applications of the platform. Ensysce is exploring the use of these technologies across multiple therapeutic areas, including non-opioid oral medicines, where abuse or overdose risk exists. With patent coverage secured through 2042, the company is well-positioned to expand its pipeline and pursue long-term partnerships or development projects. This IP strength enhances both the value and the durability of Ensysce’s innovations. We continue to execute methodically, knowing the progress made today is essential to realizing the therapeutic and commercial opportunities ahead.

0 · Reply

birdflustocks Dec. 19 at 8:27 PM

$ENSC The opioid crisis lawsuits resulted in billions of USD to be paid to relevant institutions within a few years. There is a massive public health interest. ENSC checks all the boxes for (additional) public funding: Various types of private funding used or exhausted, research progress, regulatory support, path to manufacturing, research and manufacturing partners.

1 · Reply

EnsysceBiosciences Dec. 19 at 4:59 PM

$ENSC Ensysce’s mission is to redefine how oral drugs are delivered, not by tinkering with pill coatings and formulations, but by creating a new class of oral therapies embedding safety at the molecular level. Through its proprietary platforms: TAAP™, which ensures drug activation only when taken orally, and MPAR®, which adds overdose-protection to all TAAP products. This dual-safety design reflects a deliberate shift in drug development: from formulation tweaks to chemistry-driven, patient-centric solutions. As Ensysce’s TAAP and MPAR products move through clinical development, Ensysce continues to position its capital structure to support late-stage execution and long-term value for patients and shareholders. We remain committed to transparent communication and will continue to share validated progress through public IR channels.

0 · Reply

Big_Zack22 Dec. 17 at 9:09 PM

$ENSC Running a research is not running a public company. Two things totally different.

0 · Reply

Sunnybhargava Dec. 17 at 3:19 PM

$ENSC they lowered the price so on 23 meeting they can issue more stock in same $ amount to investors

0 · Reply

garrulous Dec. 17 at 12:43 PM

$ENSC it just doesn't seem this company is on the verge of upending a multi billion dollar [global] opioid market. There's zero buzz despite what we're told are good clinical results -- zero buzz. And despite FDA BTD too, which apparently didn't put ENSC on the map at all. Great story; great concept. That aside, it's a cash burn machine; a textbook multi-year death spiral. Lastly, I listened to CEO Lynn Kirkpatrick's Spring 2022 (yes, 2022!) conference call where she said Ensysce would "represent years of shareholder value". I believe that was a direct quote, if not paraphrasing a statement that was either borne out of sheer ineptitude or a deliberate attempt to mislead shareholders. Me being one of them.

2 · Reply

ttesty Dec. 17 at 11:47 AM

A few predictions for $ENSC : (1) 1:10 reverse stock split (and then keeps falling like $AREB ). (2) cheap acquisition by Pfizer, Sanofi, Scripps - around $0.50/share. (3) private placement - around $0.50/share, (4) Lynn declares insolvency ($20M funding is basically a smoke screen). No data nor FDA approval.

0 · Reply

ttesty Dec. 17 at 9:33 AM

$ENSC is toast. Return the investors their $$ . $1 call was accurate. I'm actually gonna short to $0.75. Non-compliance (Nasdaq and FDA) o n the way too. Too little too soon. $ARTL more promising overall.

0 · Reply

Jlh50 Dec. 17 at 2:09 AM

$ENSC The website does not reflect that the phase 3 has started. It may seem like a minor point, but until the recent announcement, it was unclear as to whether the phase 3 had started. Need clear transparent communication. I do like that the company is posting information here and I’ll give props for that.

1 · Reply

CindyH0o Dec. 16 at 6:10 PM

$ENSC they have done with raising finds. Potential 30+

1 · Reply

CindyH0o Dec. 16 at 5:59 PM

$ENSC just bought 5000 shares at 1.15

0 · Reply

Market Cap	4.07M
Revenue (ttm)	5.21M
Net Income (ttm)	-7.99M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-153.36%
Debt to Equity Ratio	0.00

Volume	28,600
Avg Vol	223,422
Day's Range	N/A - N/A
Shares Out	3.63M
Stochastic %K	8%
Beta	1.15
Analysts	Strong Buy
Price Target	$16.45